|
1
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma RY, Tong TH, Leung WY and Yao KM:
Raf/MEK/MAPK signaling stimulates the nuclear translocation and
transactivating activity of FOXM1. Methods Mol Biol. 647:113–123.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katoh Y and Katoh M: Hedgehog target
genes: mechanisms of carcinogenesis induced by aberrant hedgehog
signaling activation. Curr Mol Med. 9:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang IC, Chen YJ, Hughes D, Petrovic V,
Major ML, Park HJ, Tan Y, Ackerson T and Costa RH: Forkhead box M1
regulates the transcriptional network of genes essential for
mitotic progression and genes encoding the SCF (Skp2-Cks1)
ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Costa RH: FoxM1 dances with mitosis. Nat
Cell Biol. 7:108–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okada K, Fujiwara Y, Takahashi T, Nakamura
Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori
M and Doki Y: Overexpression of forkhead box M1 transcription
factor (FOXM1) is a potential prognostic marker and enhances
chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol.
20:1035–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu M, Dai B, Kang SH, Ban K, Huang FJ,
Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, Sawaya R and Huang
S: FoxM1B is overexpressed in human glioblastomas and critically
regulates the tumorigenicity of glioma cells. Cancer Res.
66:3593–3602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yau C, Wang Y, Zhang Y, Foekens JA and
Benz CC: Young age, increased tumor proliferation and FOXM1
expression predict early metastatic relapse only for
endocrine-dependent breast cancers. Breast Cancer Res Treat.
126:803–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim IM, Ackerson T, Ramakrishna S,
Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM,
Costa RH and Kalinichenko VV: The Forkhead Box m1 transcription
factor stimulates the proliferation of tumor cells during
development of lung cancer. Cancer Res. 66:2153–2161. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu N, Zhang X, Wang X, Ge HY, Wang XY,
Garfield D, Yang P, Song YL and Bai CX: FoxM1 mediated resistance
to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol
Sin. 33:675–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kwok JM, Peck B, Monteiro LJ, Schwenen HD,
Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired
cisplatin resistance in breast cancer cells. Mol Cancer Res.
8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koeppen HK, Wright BD, Burt AD, Quirke P,
McNicol AM, Dybdal NO, Sliwkowski MX and Hillan KJ: Overexpression
of HER2/neu in solid tumours: an immunohistochemical survey.
Histopathology. 38:96–104. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaptain S, Tan LK and Chen B: Her-2/neu
and breast cancer. Diagn Mol Pathol. 10:139–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirashima N, Takahashi W, Yoshii S, Yamane
T and Ooi A: Protein overexpression and gene amplification of c-erb
B-2 in pulmonary carcinomas: a comparative immunohistochemical and
fluorescence in situ hybridization study. Mod Pathol. 14:556–562.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Berezov A, Wang Q, Zhang G,
Drebin J, Murali R and Greene MI: ErbB receptors: from oncogenes to
targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Montemurro F, Valabrega G and Aglietta M:
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase
activity. Expert Opin Biol Ther. 7:257–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia I, Vizoso F, Martin A, Sanz L,
Abdel-Lah O, Raigoso P and Garcia-Muniz JL: Clinical significance
of the epidermal growth factor receptor and HER2 receptor in
resectable gastric cancer. Ann Surg Oncol. 10:234–241. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tripathy D, Slamon DJ, Cobleigh M, Arnold
A, Saleh M, Mortimer JE, Murphy M and Stewart SJ: Safety of
treatment of metastatic breast cancer with trastuzumab beyond
disease progression. J Clin Oncol. 22:1063–1070. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J and Kang YK; ToGA
Trial Investigators. Trastuzumab in combination with chemotherapy
versus chemotherapy alone for treatment of HER2-positive advanced
gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
21
|
Carr JR, Park HJ, Wang Z, Kiefer MM and
Raychaudhuri P: FoxM1 mediates resistance to herceptin and
paclitaxel. Cancer Res. 70:5054–5063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German).
|
|
23
|
Hofmann M, Stoss O, Shi D, Buttner R, van
de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang WY, Sheehy TM, Moore LE, Hsing AW
and Purdue MP: Simultaneous recovery of DNA and RNA from
formalin-fixed paraffin-embedded tissue and application in
epidemiologic studies. Cancer Epidemiol Biomarkers Prev.
19:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McKenzie SJ, DeSombre KA, Bast BS, Hollis
DR, Whitaker RS, Berchuck A, Boyer CM and Bast RC Jr: Serum levels
of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in
human ovarian cancer. Cancer. 71:3942–3946. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dang HZ, Yu Y and Jiao SC: Prognosis of
HER2 over-expressing gastric cancer patients with liver metastasis.
World J Gastroenterol. 18:2402–2407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou F, Li N, Jiang W, Hua Z, Xia L, Wei Q
and Wang L: Prognosis significance of HER-2/neu
overexpression/amplification in Chinese patients with curatively
resected gastric cancer after the ToGA clinical trial. World J Surg
Oncol. 10:2742012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Halon A, Donizy P, Biecek P,
Rudno-Rudzinska J, Kielan W and Matkowski R: HER-2 expression in
immunohistochemistry has no prognostic significance in gastric
cancer patients. ScientificWorldJournal. 2012:9412592012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D,
Huang S, Tan D and Xie K: Critical role and regulation of
transcription factor FoxM1 in human gastric cancer angiogenesis and
progression. Cancer Res. 69:3501–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo S and Sonenshein GE: Forkhead box
transcription factor FOXO3a regulates estrogen receptor alpha
expression and is repressed by the Her-2/neu/phosphatidylinositol
3-kinase/Akt signaling pathway. Mol Cell Biol. 24:8681–8690. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Delpuech O, Griffiths B, East P, Essafi A,
Lam EW, Burgering B, Downward J and Schulze A: Induction of Mxi1-SR
alpha by FOXO3a contributes to repression of Myc-dependent gene
expression. Mol Cell Biol. 27:4917–4930. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wilson MS, Brosens JJ, Schwenen HD and Lam
EW: FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the
outcome of cancer chemotherapy. Curr Drug Targets. 12:1256–1266.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nahta R and Esteva FJ: HER2 therapy:
molecular mechanisms of trastuzumab resistance. Breast Cancer Res.
8:2152006. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhat UG, Halasi M and Gartel AL: Thiazole
antibiotics target FoxM1 and induce apoptosis in human cancer
cells. PLoS One. 4:e55922009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gusarova GA, Wang IC, Major ML,
Kalinichenko VV, Ackerson T, Petrovic V and Costa RH: A
cell-penetrating ARF peptide inhibitor of FoxM1 in mouse
hepatocellular carcinoma treatment. J Clin Invest. 117:99–111.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Radhakrishnan SK, Bhat UG, Hughes DE, Wang
IC, Costa RH and Gartel AL: Identification of a chemical inhibitor
of the oncogenic transcription factor forkhead box M1. Cancer Res.
66:9731–9735. 2006. View Article : Google Scholar : PubMed/NCBI
|
